NCCN Hematology Congress

Advances in the Management of Chronic Lymphocytic Leukemia

Phoebe Starr

October 2011, Vol 2, No 6 - NCCN Hematology Congress

New York, NY—Several advances have been made in the diagnosis and treatment of chronic lymphocytic leukemia (CLL), according to Susan O’Brien, MD, Chief, Acute Leukemia Section at M.D. Anderson Cancer Center, Houston. Treatment selection can now be guided by fluorescence in situ hybridization (FISH) testing for genetic abnormalities, and 2 new treatments in early-stage development hold promise for patients with a poor prognostic cytogenetic profile.

[ Read More ]